5 Feb 2026 CMB International Global Markets | Equity Research | Company Update Alphabet (GOOG US) Alphabet (GOOG US) - 4Q25 business performance 4Q25 results: AI continues to drive strong search and cloud business performance Alphabet reported 4Q25 results: total revenue grew by 18% YoY to US$113.8bn, 2% ahead of Bloomberg consensus estimate thanks to the strong growth of Google Search and Cloud revenue; operating income was up by 16% YoY to US$35.9bn, lower than consensus estimate of US$36.9bn, but mainly ...

5 Feb 2026 CMB International Global Markets | Equity Research | Company Update Innolight (300308 CH) Innolight (300308 CH) - Pluggables first, new architecture later Innolight's share price has experienced heightened volatility yesterday (down 5% on 4 Feb), driven by a combination of market concerns around NPO/CPO adoption, hyperscaler network roadmap evolution, upstream suppliers' capacity expansion, etc., prompting mgmt. to hold an investor Q&A session to address these issues. We believe the core investme ...

中国医药 中国医药 - 招银国际环球市场 | 睿智投资 | 行业研究 高端化和 AI 技术驱动中国体检行业长期增长 在中国人口老龄化不断加剧和居民健康意识不断提升的背景下，中国体检行业的市 场规模维持了快速增长趋势。根据中研普华的数据，中国体检行业规模在 2020 至 2024 年的年复合增长率（CAGR）为 9.2%，预计在 2024 至 2030 年将以 18.3%的 CAGR加速增长。中国体检渗透率约为 40%，远低于发达国家的 70%，意味着持续 增长的空间广阔。当前体检市场呈现"公立主导、民营追赶"的鲜明格局。根据前 瞻产业研究院的数据，公立医院占据 69%的市场份额，而民营机构的市占率提升至 24%。头部民营体检机构包括美年健康（002044 CH，未评级）、爱康国宾（未上 市）以及瑞慈医疗（1526 HK，未评级）。中国体检行业呈现出显著的高端化趋 势，头部民营体检机构均大力发展高端业务，助力提升ASP和利润率。此外，AI 技 术正成为中国体检行业突破传统瓶颈、实现高质量发展的核心引擎，而具备数据与 场景优势的龙头有望持续拉开与中小连锁的竞争身位。 2026 年 2 月 5 日 中国 医药 行业 ...

Core Insights - Pfizer reported strong Q4 2025 earnings with revenue of $17.6 billion, aligning closely with previous expectations of $18.1 billion, and adjusted net income of $3.8 billion, exceeding the prior forecast of $3.3 billion [2] - Total revenue for 2025 is projected at $62.6 billion, a 2% year-over-year decline, but operational revenue excluding COVID-19 products grew by 6%, indicating robust underlying business momentum [2] - The management reaffirmed guidance for 2026, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS ranging from $2.80 to $3.00, highlighting a year rich in catalysts [2] Company Analysis - Pfizer's pipeline includes significant catalysts such as long-acting GLP-1 and Amylin projects, with key data readouts expected in 2026 [2] - The VESPER-3 study demonstrated a 12.3% weight loss effect at the 28-week mark for the mid-dose group of PF'3944, with predictions suggesting a 15.8% weight loss for the high-dose group [6] - The company plans to initiate a Phase 3 study for PF'3944 later this year, with further updates on its obesity product portfolio expected [6][7] Market Performance - The Hang Seng Index closed at 26,847, reflecting a slight increase of 0.05% for the day and a year-to-date gain of 4.75% [2] - The U.S. stock market saw declines, particularly in technology and consumer discretionary sectors, while energy and materials sectors showed strength [4] - Notable movements included a 17% drop in AMD shares following weak guidance, impacting the semiconductor sector [4]

Investment Rating - The report maintains a "Buy" rating for Pfizer Inc. (PFE US) with a target price of $35.46, down from the previous target of $36.16, reflecting a potential upside of 32.4% from the current price of $26.78 [5][7]. Core Insights - Pfizer reported strong Q4 2025 results with revenues of $17.6 billion, aligning closely with the forecast of $18 billion. Adjusted net income was $3.8 billion, exceeding the estimate of $3.3 billion. Excluding COVID-19 products, operational revenue grew by 6% year-over-year, indicating a robust business foundation [3]. - The management reiterated revenue guidance for 2026 at $59.5 billion to $62.5 billion, with adjusted EPS projected between $2.80 and $3.00. Anticipated catalysts for 2026 include key data releases for long-acting GLP-1 and insulin projects, as well as positive clinical progress for obesity products and PF'4404 [3][5]. - The VESPER-3 study results for PF'3944 showed a 12.3% weight reduction at the medium dose, with expectations for the high dose to achieve a 15.8% reduction, positioning it competitively against alternatives [4]. - Pfizer is rapidly advancing the integration of PF'4404 (PD-1/VEGF) with its leading ADC product portfolio, aiming to establish a dominant position in the oncology market [5]. Financial Summary - For FY2026, revenue is projected at $60.7 billion, with a year-over-year decline of 2.9%. Adjusted net income is expected to be $16.34 billion, reflecting an 8.8% decrease from the previous year [6][16]. - The report outlines a decrease in P/E ratios, with FY2026 expected at 14.1x, down from 19.6x in FY2024, indicating a shift in valuation metrics [6][17]. - The DCF valuation estimates a share value of $35.46, based on a WACC of 9.95% and a terminal growth rate of 2.0% [13][14].

Market Performance - The Hang Seng Index closed at 26,847, with a slight increase of 0.05% for the day and a year-to-date increase of 4.75% [1] - The Hang Seng Technology Index decreased by 1.84% for the day and is down 2.71% year-to-date [1] - The US stock market saw the Dow Jones increase by 0.53%, while the S&P 500 and Nasdaq fell by 0.51% and 1.51%, respectively [1] Sector Performance - In the Hong Kong market, the financial sector increased by 0.66% and is up 8.51% year-to-date, while the industrial sector decreased by 0.48% [2] - The real estate sector in Hong Kong saw a significant increase of 1.99% for the day and is up 17.13% year-to-date [2] Capital Flows - Southbound funds recorded a net inflow of 13.373 billion HKD, with Tencent, Alibaba, and Xiaomi being the top net buyers [3] - In contrast, SMIC, Hua Hong Semiconductor, and Jun Da Co. were the most sold stocks [3] US Market Trends - The US stock market experienced a sell-off in technology stocks, particularly in software and semiconductor sectors, with AMD's weak guidance leading to a 17% drop [3] - The S&P 500 software sector has seen an average decline of 25% since reaching a historical high last October [3] Company Analysis: Pfizer (PFE US) - Pfizer reported strong Q4 2025 earnings with revenue of 17.6 billion USD, slightly below the expected 18.1 billion USD, but adjusted net income exceeded expectations at 3.8 billion USD [4] - The company anticipates 2026 revenue between 59.5 billion to 62.5 billion USD, with adjusted EPS guidance of 2.80 to 3.00 USD [4] - Key upcoming milestones include data readouts for long-acting GLP-1 and Amylin projects, which are expected to drive significant valuation re-evaluation [4] Clinical Developments - Pfizer's VESPER-3 study showed a 12.3% weight loss effect at the 28-week mark for its long-acting GLP-1 candidate, with a potential 15.8% weight loss projected for a higher dose [5] - The company plans to initiate a Phase 3 study for the higher dose later this year, with detailed data expected at the ADA conference in June [5] Oncology Pipeline - Pfizer is advancing its PD-1/VEGF and ADC combination therapies, with ongoing Phase 3 trials for PF'4404 in colorectal cancer and additional trials planned for 2026 [6] - The market narrative is shifting towards pipeline execution strength, with obesity products and PF'4404 clinical progress expected to drive stock price increases [6]

Market Performance - The Hang Seng Index closed at 26,835, up 0.22% for the day and up 4.70% year-to-date [1] - The Shanghai Composite Index closed at 4,068, up 1.29% for the day and up 2.49% year-to-date [1] - The US markets saw declines, with the Dow Jones down 0.34% and the S&P 500 down 0.84% [1] Sector Performance - The Hang Seng Financial Index rose by 0.99% with a year-to-date increase of 7.80% [2] - The Hang Seng Real Estate Index increased by 1.65%, showing a year-to-date growth of 14.84% [2] - The Hang Seng Technology Index fell by 1.07%, with a year-to-date decline of 0.88% [1][2] Chinese Stock Market Insights - The Chinese stock market rebounded, with materials, industrials, and defense sectors leading gains, while information technology and telecommunications sectors declined [3] - Southbound capital saw a net inflow of HKD 952 million, with Tencent, China Mobile, and Xiaomi being the top net buyers [3] - Concerns over potential VAT increases on financial and internet services led to declines in internet platform stocks, although these rumors were debunked by experts [3] Aluminum Industry Analysis - The global supply of electrolytic aluminum is expected to remain tight until 2026, supporting higher aluminum prices, projected to increase by 15% year-on-year [4] - China's electrolytic aluminum capacity utilization is nearing saturation, with a forecasted capacity limit of 45 million tons by December 2025 [4] - The report initiates coverage on Innovation Industries (2788 HK) with a "Buy" rating and a target price of HKD 32, citing cost advantages from green energy and expansion in Saudi Arabia [7] Insurance Industry Insights - The insurance sector in China is projected to see premium income growth, with life insurance premiums expected to reach CNY 3.56 trillion, a year-on-year increase of 11.4% [5] - December saw a recovery in premium income, with life insurance premiums growing by 10.1% year-on-year [5] - The report maintains a positive outlook on the insurance sector, recommending stocks like China Ping An (2318 HK) and AIA Group (1299 HK) with target prices of HKD 90 and HKD 89, respectively [7]

Investment Rating - The report maintains a "BUY" rating for China Hongqiao, with a revised target price of HK$45, up from HK$39, reflecting a 27.5% upside potential from the current price of HK$35.30 [1][3]. Core Insights - The global aluminium deficit is expected to persist through 2026-27, driven by high utilization rates in China and limited new capacity overseas. This is anticipated to lead to a 15% year-on-year increase in aluminium prices in 2026 [1][7]. - Earnings forecasts have been revised upwards, with a projected core net profit of RMB26.2 billion for 2025, representing a 7% year-on-year growth, and an acceleration to 34% growth in 2026, primarily due to higher aluminium prices [1][7]. - The report indicates that a 1% increase in aluminium prices could boost 2026 earnings by 2.3%, while a 1% decrease in coal prices would increase earnings by 0.3% [1][7]. Financial Summary - Revenue projections for China Hongqiao are as follows: RMB156,596 million for 2025, RMB167,859 million for 2026, and RMB162,737 million for 2027, with respective year-on-year growth rates of 0.3%, 7.2%, and -3.1% [2][26]. - Adjusted net profit is forecasted to be RMB26,262.3 million for 2025, RMB36,049.2 million for 2026, and RMB32,879.0 million for 2027, with corresponding earnings per share (EPS) of RMB2.71, RMB3.63, and RMB3.31 [2][26]. - The price-to-earnings (P/E) ratio is projected to be 12.7x for 2025, 8.7x for 2026, and 9.5x for 2027, indicating a favorable valuation compared to historical averages [2][26]. Market and Share Performance - The market capitalization of China Hongqiao is approximately HK$350.3 billion, with an average turnover of HK$1,565.4 million over the past three months [4]. - The share price has shown significant performance, with a 73.5% increase over the past six months [6].

Investment Rating - The report initiates coverage of Chuangxin Industries with a BUY rating and a target price (TP) of HK$32, representing a 28% upside from the current price of HK$25 [3][8]. Core Insights - Chuangxin Industries presents a unique growth opportunity in the aluminium sector, driven by capacity expansion in Saudi Arabia and a significant cost advantage due to low green energy costs in China [1]. - The ongoing development of wind and solar power sources is expected to further reduce electricity costs by 2026-2027, enhancing profitability [1]. - The tight supply in the aluminium market is anticipated to support higher aluminium prices, with a 1% increase in aluminium prices projected to boost Chuangxin's earnings by 2.5% in 2026 [1]. Financial Summary - Revenue is projected to grow from RMB 13,815 million in FY23A to RMB 20,091 million in FY27E, with a notable increase of 29.1% in FY26E [2]. - Adjusted net profit is expected to rise significantly from RMB 1,003.6 million in FY23A to RMB 4,819.4 million in FY27E, reflecting strong growth potential [2]. - The earnings per share (EPS) is forecasted to increase from RMB 0.67 in FY23A to RMB 2.32 in FY27E, indicating robust profitability growth [2]. Capacity Expansion - Chuangxin currently operates 788 kt of electrolytic aluminium capacity in China and is expanding with a 500 kt project in Saudi Arabia, expected to be completed by Q2 2027 [7][14][16]. - The company has a high self-sufficiency rate for electricity, with plans to achieve over 50% of its power supply from green energy by 2027, significantly reducing costs [25][34][37]. Cost Structure - The current electricity cost for Chuangxin is RMB 0.33/kWh, lower than the industry average of RMB 0.40/kWh, with expectations to reduce this further to below RMB 0.20/kWh through green energy initiatives [25][37]. - The company’s captive coal-fired power plants provide 100% electricity self-sufficiency for aluminium smelting, enhancing its cost leadership in the sector [24][25]. Market Position - Chuangxin is positioned as a significant player in the aluminium market, being the 12th largest electrolytic aluminium producer in China as of 2024 [7]. - The company has established a strong customer base, with a significant portion of its revenue derived from major clients in the non-ferrous metal processing sector [39][41].

Report Summary 1. Report Industry Investment Rating - Not provided in the given content. 2. Core Viewpoints - The Macau gaming industry showed a solid start in 2026 with a 24% year-on-year growth in January's GGR, reaching 90.7% of the January 2019 level. The 2026 GGR target of MOP236bn seems conservative based on the 2025 growth momentum [7][10][11]. - In the fixed - income market, there were various price movements across different sectors such as Chinese/HK higher - yielding space, Chinese properties, SE Asian space, etc. Some bonds tightened while others widened or declined in price [2]. - Chinese IG KUAISH/MEITUA recovered and tightened 1 - 3bps in the morning [3]. 3. Summary by Directory Trading Desk Comments - In the FRN space, there were balanced two - way flows across AU/JP financial names, MAYMK, 2 - 3yr Korean quasi - sovereign issues, and HYNMTR, with the latter closing 1 - 2bps tighter. Front - end to belly Chinese AMC papers, POE/TMTs, and belly financial papers saw initial selling, widening spreads by 1 - 3bps, but spreads largely closed unchanged. TW lifers widened 3 - 5bps, and the Macau gaming complex had a range of - 0.2pt to + 0.1pt change. In Chinese/HK higher - yielding space, WESCHI 26 rose 1.4pts and WESCHI 28 edged 0.2pt higher, while EHICAR 26 - 27 dropped 0.7 - 2.3pts. In Chinese properties, VNKRLE 27 - 29 were 0.9 - 1.7pts lower. In SE Asian space, VLLPM 27 - 29 dived 7.6 - 9.6pts [2]. - In the morning, Chinese IG KUAISH/MEITUA recovered and tightened 1 - 3bps. RMs were buying perps, and PBs were switching out of short - dated to call EU AT1s. ACPM 4.85 Perp/FAEACO 12.814 Perp were 0.7 - 0.9pt lower, and NWDEVL 27 - 28 recovered 0.5 - 0.6pt [3]. Macro News Recap - On Monday, S&P (+0.54%), Dow (+1.05%), and Nasdaq (+0.56%) were higher. The S&P Global Manufacturing January 2026 PMI was 52.4 (higher than the expected 51.9), ISM Manufacturing January 2026 Prices was 59.0 (lower than the expected 59.3), and ISM Manufacturing January 2026 PMI was 52.6 (higher than the expected 48.5). The UST yield was higher, with 2/5/10/30 - year yields at 3.57%/3.83%/4.29%/4.90% [6]. Desk Analyst Comments - Macau's gross gaming revenue (GGR) in January 2026 increased 24.0% year - on - year to MOP22.6bn, representing 90.7% of the January 2019 GGR and being the highest January figure since 2019. The 2026 GGR target of MOP236bn seems conservative as GGR in 2025 increased 9.1% to MOP247.4bn, exceeding the revised forecast of MOP228bn. The 2026 forecast represents a 3.5% year - on - year growth from the 2025 revised GGR forecast. In 2025, Macau's tourist arrival was 40.1mn, a 15% year - on - year increase and exceeding the 2019 record [7][10][11]. - Macau gaming bonds are considered lower - beta and good carry plays. Top picks are MPELs and STCITYs, and WYNMAC'27 and '29 are yield pick - up plays. The report is neutral on MGMCHIs, SANLTDs, and SJMHOLs [13]. Offshore Asia New Issues - Priced: CMBC International Funding (HK) issued USD300mn with a 3 - year tenor at SOFR + 60, rated - / - /BBB - [17]. - Pipeline: No offshore Asia new issues pipeline on this day [18]. News and Market Color - There were 89 credit bonds issued onshore yesterday with an amount of RMB88bn. No credit bonds were issued on 2 Feb 2025 due to the Chinese New Year holiday. Trump said he would roll back 25% punitive tariffs and cut the levy on Indian goods to 18% from 25% in return for India stopping buying Russian oil. China's local government debt increased 15% in 2025 and remains manageable. Indonesia's coal exports declined 19.7% last year to USD24.5bn due to falling global prices. Huatai Securities raised USD698.6mn by selling HKD and RMB - denominated guaranteed bonds due 2028. UPL Limited 9MFY26 EBITDA rose 22% year - on - year to INR59.1bn (cUSD648mn) [19][20].